Abstract
The protease, human kallikrein-related peptidase 6 (hK6) is derived from activated macrophages in the central nervous system (CNS) and may contribute to pathology observed in multiple sclerosis (MS). In the present study, we compared serum and cerebrospinal fluid (CSF) protein concentrations of human kallikrein-related peptidase 6 derived from neurological controls and patients diagnosed with advanced multiple sclerotic disease. Mean serum levels of human kallikrein-related peptidase 6 were similar in neurological controls and patients diagnosed with relapsing-remitting (RR), secondary progressive (SP) and primary progressive (PP) multiple sclerosis with mean levels ranging from 3.5 to 3.75 ng/ml. Patients diagnosed with advanced multiple sclerosis showed mean CSF levels (29 ng/ml) that were significantly higher than neurological controls (25.5 ng/ml). Determining CSF concentrations of human kallikrein-related peptidase 6 may therefore have diagnostic value in MS.
Keywords: hK6, serum, CSF, RRMS, SPMS, PPMS, human kallikrein-related peptidase 6, central nervous system, cerebrospinal fluid, protease, inflammatory lesions, encephalomyelitis, ELISA, Tetramethylbenzidine, Alzheimer's disease, EDSS
Current Drug Discovery Technologies
Title: Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Volume: 7 Issue: 2
Author(s): Andrea L.O. Hebb, Virender Bhan, Alexander D. Wishart, Craig S. Moore and George S. Robertson
Affiliation:
Keywords: hK6, serum, CSF, RRMS, SPMS, PPMS, human kallikrein-related peptidase 6, central nervous system, cerebrospinal fluid, protease, inflammatory lesions, encephalomyelitis, ELISA, Tetramethylbenzidine, Alzheimer's disease, EDSS
Abstract: The protease, human kallikrein-related peptidase 6 (hK6) is derived from activated macrophages in the central nervous system (CNS) and may contribute to pathology observed in multiple sclerosis (MS). In the present study, we compared serum and cerebrospinal fluid (CSF) protein concentrations of human kallikrein-related peptidase 6 derived from neurological controls and patients diagnosed with advanced multiple sclerotic disease. Mean serum levels of human kallikrein-related peptidase 6 were similar in neurological controls and patients diagnosed with relapsing-remitting (RR), secondary progressive (SP) and primary progressive (PP) multiple sclerosis with mean levels ranging from 3.5 to 3.75 ng/ml. Patients diagnosed with advanced multiple sclerosis showed mean CSF levels (29 ng/ml) that were significantly higher than neurological controls (25.5 ng/ml). Determining CSF concentrations of human kallikrein-related peptidase 6 may therefore have diagnostic value in MS.
Export Options
About this article
Cite this article as:
L.O. Hebb Andrea, Bhan Virender, D. Wishart Alexander, S. Moore Craig and S. Robertson George, Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis, Current Drug Discovery Technologies 2010; 7 (2) . https://dx.doi.org/10.2174/157016310793180611
DOI https://dx.doi.org/10.2174/157016310793180611 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate and Related Steroids: Their Role in Inflammatory, Allergic and Immunological Disorders
Current Drug Targets - Inflammation & Allergy Bridged Piperazines and Piperidines as CCR1 Antagonists with Oral Activity in Models of Arthritis and Multiple Sclerosis
Letters in Drug Design & Discovery Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells
Current Immunology Reviews (Discontinued) Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Histamine H4 Receptors and their Significance
Current Immunology Reviews (Discontinued) Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology The Proteasome in Health and Disease
Current Pharmaceutical Design Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Engineering Simulations for Cancer Systems Biology
Current Drug Targets Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Non-Analgesic Effects of Opioids: Mechanisms and Potential Clinical Relevance of Opioid-Induced Immunodepression
Current Pharmaceutical Design Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) A Central Role for ATP Signalling in Glial Interactions in the CNS
Current Drug Targets Graphical Abstracts
Current Neuropharmacology Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued)